SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
1.820
-0.130 (-6.67%)
At close: Feb 21, 2025, 4:00 PM
1.760
-0.060 (-3.30%)
After-hours: Feb 21, 2025, 4:57 PM EST

SAB Biotherapeutics Revenue

SAB Biotherapeutics had revenue of $1.51M in the twelve months ending September 30, 2024, down -63.06% year-over-year. In the year 2023, SAB Biotherapeutics had annual revenue of $2.24M, down -90.63%.

Revenue (ttm)
$1.51M
Revenue Growth
-63.06%
P/S Ratio
10.38
Revenue / Employee
$26,539
Employees
57
Market Cap
16.80M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.24M-21.67M-90.63%
Dec 31, 202223.90M-36.97M-60.73%
Dec 31, 202160.88M5.64M10.21%
Dec 31, 202055.24M51.80M1,504.91%
Dec 31, 20193.44M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings